Edwards Lifesciences Stock Price, News & Analysis (NYSE:EW) $67.43 +0.33 (+0.49%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$67.14▼$68.3150-Day Range$61.72▼$73.7052-Week Range$60.57▼$94.87Volume3.14 million shsAverage Volume4.01 million shsMarket Capitalization$40.90 billionP/E Ratio28.82Dividend YieldN/APrice Target$82.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside22.8% Upside$82.78 Price TargetShort InterestHealthy1.80% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.53Based on 20 Articles This WeekInsider TradingSelling Shares$12.61 M Sold Last QuarterProj. Earnings Growth11.95%From $2.51 to $2.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.79 out of 5 starsMedical Sector59th out of 949 stocksSurgical Appliances & Supplies Industry4th out of 20 stocks 3.2 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 8 buy ratings, 8 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $82.78, Edwards Lifesciences has a forecasted upside of 22.8% from its current price of $67.43.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.80% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 6.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.0 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Edwards Lifesciences this week, compared to 8 articles on an average week.Search InterestOnly 12 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 45 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,609,879.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.25% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 11.95% in the coming year, from $2.51 to $2.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 28.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 28.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.29.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 3.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 6.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comInvesting in Edwards Lifesciences (NYSE:EW) five years ago would have delivered you a 28% gainNovember 29, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Lowered to "Underperform" at Wolfe ResearchNovember 30, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. November 28, 2023 | markets.businessinsider.comEdwards Lifesciences Sell Rating: Anticipating Market Headwinds and Margin PressuresNovember 28, 2023 | za.investing.comEdwards Lifesciences cut by Wolfe Research on risk of US TAVR disappointingNovember 28, 2023 | msn.comEdwards Lifesciences slips as Wolfe downgrades on emerging rivalryNovember 28, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Upgraded at StockNews.comNovember 24, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Up 6.8% Since Last Earnings Report: Can It Continue?November 30, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. November 24, 2023 | americanbankingnews.comFY2024 EPS Estimates for Edwards Lifesciences Co. (NYSE:EW) Lifted by Leerink PartnrsNovember 17, 2023 | finance.yahoo.comEdwards Lifesciences (NYSE:EW) Has More To Do To Multiply In Value Going ForwardNovember 5, 2023 | finance.yahoo.comGreat week for Edwards Lifesciences Corporation (NYSE:EW) institutional investors after losing 2.1% over the previous yearNovember 3, 2023 | msn.comUnusual Put Option Trade in Edwards Lifesciences (EW) Worth $7,378.00KNovember 1, 2023 | benzinga.comHere's How Much $100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth TodayOctober 27, 2023 | msn.comEdwards Lifesciences posts lower-than-expected sales of heart device; shares fallOctober 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO) and Edwards Lifesciences (EW)October 27, 2023 | markets.businessinsider.comEdwards Lifesciences’ Strong Market Position and Potential Growth Despite Slowdown: An Optimistic OutlookOctober 27, 2023 | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) Q3 2023 Earnings Call TranscriptOctober 27, 2023 | seekingalpha.comEdwards Lifesciences Q3: Clinical Trial Updates ImpressOctober 26, 2023 | msn.comBoston Scientific, Edwards Lifesciences Tumble As Guidance 'Noise' Slams The LatterOctober 26, 2023 | markets.businessinsider.comHold Rating on Edwards Lifesciences: Evaluating TAVR Growth Potential, Margin Expansion, and Revised Price ObjectiveOctober 26, 2023 | markets.businessinsider.comEdwards Lifesciences’ Promising Growth Trends Elicit ‘Buy’ Rating Despite SetbacksOctober 26, 2023 | finance.yahoo.comWhy Edwards Lifesciences Stock Plummeted TodayOctober 26, 2023 | seekingalpha.comEdwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing MarketsOctober 26, 2023 | ca.investing.comEdwards Lifesciences tumbles as guidance misses expectationsOctober 26, 2023 | finanznachrichten.deEdwards Lifesciences Corporation: Edwards Lifesciences Reports Third Quarter ResultsOctober 26, 2023 | finance.yahoo.comTRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATIONSee More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/25/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)1/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees17,300Year Founded1958Price Target and Rating Average Stock Price Target$82.78 High Stock Price Target$107.00 Low Stock Price Target$57.00 Potential Upside/Downside+22.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$2.34 Trailing P/E Ratio28.82 Forward P/E Ratio26.86 P/E Growth3.74Net Income$1.52 billion Net Margins24.59% Pretax Margin28.11% Return on Equity24.54% Return on Assets17.40% Debt Debt-to-Equity Ratio0.09 Current Ratio3.28 Quick Ratio2.45 Sales & Book Value Annual Sales$5.38 billion Price / Sales7.60 Cash Flow$2.74 per share Price / Cash Flow24.57 Book Value$11.09 per share Price / Book6.08Miscellaneous Outstanding Shares606,500,000Free Float598,676,000Market Cap$40.90 billion OptionableOptionable Beta1.02 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 55)CEO & Director Comp: $1.04MMr. Scott B. Ullem (Age 56)Corporate VP & CFO Comp: $1.09MMr. Larry L. Wood (Age 57)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.1MMr. Jean-Luc Lemercier (Age 66)Corporate Vice President of Japan, Asia Pacific & Greater China Comp: $1.24MDr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 64)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMr. Donald E. Bobo Jr. (Age 61)Corporate Vice President of Strategy & Corporate Development Comp: $1.26MMs. Christine Z. McCauley (Age 58)Corporate Vice President of Human Resources More ExecutivesKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNSmith & NephewNYSE:SNNView All CompetitorsInsiders & Institutions2Xideas AGSold 3,552 shares on 11/27/2023Ownership: 0.023%Banque Pictet & Cie SASold 2,480 shares on 11/27/2023Ownership: 0.002%Deutsche Bank AGBought 807,502 shares on 11/24/2023Ownership: 0.452%EP Wealth Advisors LLCBought 14,035 shares on 11/24/2023Ownership: 0.007%Graham Capital Management L.P.Sold 5,081 shares on 11/22/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EW Stock Analysis - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price target for 2024? 18 brokers have issued 12-month price targets for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they predict the company's stock price to reach $82.78 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2023? Edwards Lifesciences' stock was trading at $74.61 at the beginning of 2023. Since then, EW shares have decreased by 9.6% and is now trading at $67.43. View the best growth stocks for 2023 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 10,750,000 shares, a decline of 6.3% from the October 31st total of 11,470,000 shares. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is presently 2.6 days. Currently, 1.8% of the company's stock are short sold. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 30th 2024. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) issued its earnings results on Wednesday, October, 25th. The medical research company reported $0.59 EPS for the quarter, hitting analysts' consensus estimates of $0.59. The medical research company earned $1.48 billion during the quarter, compared to analyst estimates of $1.48 billion. Edwards Lifesciences had a net margin of 24.59% and a trailing twelve-month return on equity of 24.54%. Edwards Lifesciences's revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 EPS. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS), Goldman Sachs Future Health Care Equity ETF (GDOC) and Inspire 100 ETF (BIBL). When did Edwards Lifesciences' stock split? Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its FY23 earnings guidance on Wednesday, October, 25th. The company provided earnings per share (EPS) guidance of $2.50-2.60 for the period, compared to the consensus EPS estimate of $2.55. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (2.90%), Brown Advisory Inc. (2.49%), Morgan Stanley (1.17%), Northern Trust Corp (1.05%), Legal & General Group Plc (0.75%) and Sands Capital Management LLC (0.75%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More This page (NYSE:EW) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.